June 9, 2020 8:13am

How algorithms surmounted optimism stimulating a brutal circle back

News: Global Blood Therapeutics (GBT) expand the potential use of Oxbryta® (voxelotor) for the treatment of sickle cell disease (SCD) in children ages 4 to 11 years, following a Type B meeting with the U.S. FDA. Indication. Brainstorm Cell Therapeutics (BCLI) with news that the ALS Association and I AM ALS have awarded a combined grant of $500,000 to BCLI.

Pre-open indications: 7 BUYs and 2 SELLs     

What I provide is an “intelligence daily” to “never leave an investor uninformed”!  Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors who make money and for those who read and don’t weep!

Can you afford NOT to read it?

Members only. Please login.